GH Research (NASDAQ:GHRS) Coverage Initiated by Analysts at Guggenheim

Guggenheim started coverage on shares of GH Research (NASDAQ:GHRS) in a report released on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $32.00 target price on the stock.

Several other research firms have also recently weighed in on GHRS. Cantor Fitzgerald began coverage on GH Research in a research report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective for the company. Canaccord Genuity Group lowered their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of GH Research in a research note on Monday, January 27th. Royal Bank of Canada initiated coverage on shares of GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Stifel Nicolaus upped their price target on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $30.86.

GH Research Price Performance

Shares of GHRS stock opened at $10.88 on Thursday. The stock’s 50-day moving average is $11.09 and its two-hundred day moving average is $9.19. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The firm has a market cap of $566.06 million, a P/E ratio of -13.77 and a beta of 0.94.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. As a group, research analysts expect that GH Research will post -0.8 EPS for the current year.

Hedge Funds Weigh In On GH Research

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in GH Research during the fourth quarter valued at approximately $44,000. Two Sigma Investments LP acquired a new stake in shares of GH Research in the fourth quarter valued at approximately $117,000. Millennium Management LLC bought a new stake in GH Research during the 4th quarter worth about $145,000. AdvisorShares Investments LLC boosted its position in GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after purchasing an additional 4,806 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after buying an additional 8,641 shares during the last quarter. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).